1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine has been researched along with aspartic acid in 1 studies
Studies (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Trials (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Recent Studies (post-2010) (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Studies (aspartic acid) | Trials (aspartic acid) | Recent Studies (post-2010) (aspartic acid) |
---|---|---|---|---|---|
9 | 0 | 2 | 23,005 | 417 | 4,018 |
Protein | Taxonomy | 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine (IC50) | aspartic acid (IC50) |
---|---|---|---|
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 1.638 | |
Excitatory amino acid transporter 1 | Homo sapiens (human) | 90.1265 | |
Excitatory amino acid transporter 2 | Homo sapiens (human) | 11 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 1.638 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 1.638 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 1.638 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 1.638 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 1.638 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 1.638 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
1 other study(ies) available for 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine and aspartic acid
Article | Year |
---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |